|
|
Frank A. Bonsal, Jr. Mr. Bonsal was a founding member of Red Abbey Venture Partners. Mr. Bonsal was also a founding partner of New Enterprise Associates (NEA), one of the country’s largest venture capital firms. During his tenure at NEA, Mr. Bonsal served on the Board of Directors of a number of life sciences companies, including Aspect Medical Systems, Inc. (NASDAQ: ASPM), Biopure Corporation (NASDAQ: BPUR), Cantab Pharmaceuticals PLC (acquired by Xenova Group PLC), GeneScreen, Inc. (acquired by Orchid Biosciences, Inc.), IBAH, Inc. (acquired by Omnicare, Inc.), Molecular Tool, Inc. (acquired by Orchid Biosciences, Inc.), Synaptic Pharmaceuticals Corporation (acquired by H. Lundbeck A/S), and Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX). Additionally, Mr. Bonsal played an active role in a number of NEA’s life sciences investments, including Alkermes, Inc. (NASDAQ: ALKS), Anadys Pharmaceuticals, Inc., Bethesda Research Laboratories, Inc. (acquired by Life Technologies, Inc.), Dura Pharmaceuticals, Inc. (acquired by Elan Corporation), GelTex Pharmaceuticals, Inc. (acquired by Genzyme General), Genetic Therapy, Inc. (acquired by Sandoz), Pyxis Corporation (acquired by Cardinal Health, Inc.) and Sepracor, Inc. (NASDAQ: SEPR). *****
|
|
||||||||||
Copyright © 2004 - 2008 • RED
ABBEY VENTURE PARTNERS • All
Rights Reserved |